Navigation Links
Cancer stem cell subpopulation drives metastasis of human pancreatic cancer
Date:9/12/2007

Scientists have identified a distinct subpopulation of cancer stem cells (CSCs) that is responsible for metastasis of a deadly human pancreatic cancer. The research, published by Cell Press in the September issue of the journal Cell Stem Cell, provides insight into the role of CSCs in cancer initiation, progression, and metastasis and suggests new directions for development of more effective therapeutics.

Pancreatic adenocarcinoma ranks as the fourth leading cause of cancer death and is relatively incurable due to early metastatic spread and high resistance to radiation and chemotherapy. In order to better understand the pathology of this deadly cancer, scientists have recently begun to explore the role of CSCs in pancreatic tumors. CSCs are thought to be a small population of tumor cells that have similar properties to normal stem cells in that they are self-replicating and capable of giving rise to populations of differentiated cells. Dr. Christopher Heeschen from the Department of Surgery at Ludwig-Maximilians-University in Munich, Germany led a study to examine the role of CSCs in pancreatic cancer.

The researchers discovered that human pancreatic cancer tissue contains tumorigenic and chemotherapy resistant stem cells defined by expression of CD133, a surface marker expressed by a variety of normal and malignant stem cells. They identified a distinct subset of cells expressing both CD133 and the chemokine receptor CXCR4, which plays a key role in blood cell migration, in the invasive front of the tumor. Implantation of isolated CD133+/CXCR4+ cells into mice resulted in metastatic tumor development, identifying them as CSCs. Cancer metastasis was abolished by inhibiting CXCR4 or by transplanting CD133+/CXCR4- cells instead, underlining the importance of CXCR4 for the invasive cell behavior. Clinical studies revealed that tumor samples with a high number of CXCR4+ cells were more migratory and came from patients that suffered from more advanced metastatic disease. This important correlation may provide more accurate individual prognoses, allowing for improved selection of therapeutic agents.

These findings demonstrate for the first time that a specific CD133+/CXCR4+ cancer stem cell population present at the tumor-host interface is critically involved in pancreatic tumor metastasis. The further molecular characterization of the pancreatic CSCs identified in the present study will be crucial for the development of new therapeutic strategies to eliminate these tumorigenic and metastatic cells. This may eventually provide a more effective treatment for our patients suffering from this deadly disease. In this respect, the demonstrated possibility of expanding pancreatic CSCs in vitro will dramatically help us in the evaluation of drug efficacy, offers Dr. Heeschen.


'/>"/>

Contact: Nancy Wampler
nwampler@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Vitamin B12 can help in detecting cancers
6. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
7. Consensus on "Combination Therapy" for Breast Cancer
8. Cancers of Colon & Rectum linked to Cigarette Smoking
9. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
10. The Cancer Rumour mill working over time
11. Want skin cancer? Please have a cigarette
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today it will exhibit ... Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, ... to improve Medicaid population health management. , ODH will also have an exhibit booth ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ability to ... Studios. With ProSharpen Color users have total control over sharpening amount, sharpening radius, threshold, ... With color spectrum tools users can visually see the color range effected with ease ...
(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – Edition 2017 ... initiated a second print-run of its lavish luxury travel coffee table book. , ... in at more than six kilos, retails at EUR 1,000 per copy and is ...
(Date:2/24/2017)... ... , ... Dr. Ronald E. Hawkins, vice president for academic ... A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of ... comes to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... and hearing disabilities, it is so critically important that we all are aware ... That is why Mediaplanet is proud to announce the launch of its newest ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology: